Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 13 09 2019
revised: 11 01 2020
accepted: 29 01 2020
pubmed: 18 2 2020
medline: 10 4 2021
entrez: 18 2 2020
Statut: ppublish

Résumé

We pooled multiethnic data from four population-based studies and examined associations of menstrual and reproductive characteristics with breast cancer (BC) risk by tumor hormone receptor (HR) status [defined by estrogen receptor (ER) and progesterone receptor (PR)]. We estimated odds ratios and 95% confidence intervals using multivariable logistic regression, stratified by age (<50, ≥50 years) and ethnicity, for 5,186 HR+ (ER+ or PR+) cases, 1,365 HR- (ER- and PR-) cases and 7,480 controls. For HR+ BC, later menarche and earlier menopause were associated with lower risk in non-Hispanic whites (NHWs) and Hispanics, and higher parity and longer breast-feeding were associated with lower risk in Hispanics and Asian Americans, and suggestively in NHWs. Positive associations with later first full-term pregnancy (FTP), longer interval between menarche and first FTP and shorter time since last FTP were limited to younger Hispanics and Asian Americans. Except for nulliparity, reproductive characteristics were not associated with risk in African Americans. For HR- BC, lower risk was associated with later menarche, except in African Americans and older Asian Americans and with longer breast-feeding in Hispanics and Asian Americans only. In younger African Americans, HR- BC risk associated with higher parity (≥3 vs. 1 FTP) was increased fourfold in women who never breast-fed, but not in those with a breast-feeding history, suggesting that breast-feeding may mitigate the adverse effect of higher parity in younger African American women. Further work needs to evaluate why menstrual and reproductive risk factors vary in importance according to age and ethnicity.

Identifiants

pubmed: 32064598
doi: 10.1002/ijc.32923
pmc: PMC8784189
mid: NIHMS1653255
doi:

Substances chimiques

Receptors, Estrogen 0
Receptors, Progesterone 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1808-1822

Subventions

Organisme : NCI NIH HHS
ID : CA077305
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA199343
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA078552
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000036C
Pays : United States
Organisme : NCI NIH HHS
ID : CA078802
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063446
Pays : United States
Organisme : NCI NIH HHS
ID : CA078762
Pays : United States
Organisme : NCI NIH HHS
ID : CA078552
Pays : United States
Organisme : NCI NIH HHS
ID : CA063446
Pays : United States
Organisme : NCI NIH HHS
ID : CA078682
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA078762
Pays : United States
Organisme : NCI NIH HHS
ID : CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : CA199343
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP000807
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA078802
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA078682
Pays : United States

Informations de copyright

© 2020 UICC.

Références

Breast Cancer Res. 2014 Jul 08;16(4):R74
pubmed: 25005139
Breast Cancer Res Treat. 2014 Feb;144(1):1-10
pubmed: 24477977
Int J Cancer. 2018 Jun 1;142(11):2273-2285
pubmed: 29330856
Lancet Oncol. 2012 Nov;13(11):1141-51
pubmed: 23084519
Breast Cancer Res Treat. 2014 Jun;145(3):567-79
pubmed: 24820413
Cancer Treat Rev. 2016 Sep;49:65-76
pubmed: 27529149
Epidemiol Rev. 1993;15(1):36-47
pubmed: 8405211
Br J Cancer. 2002 Mar 4;86(5):723-7
pubmed: 11875733
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1883-91
pubmed: 21846820
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1666-72
pubmed: 26464428
J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
pubmed: 21191117
Breast Cancer Res. 2019 Mar 28;21(1):46
pubmed: 30922380
Breast Cancer Res. 2017 Nov 7;19(1):119
pubmed: 29116004
Eur J Cancer Clin Oncol. 1988 Jan;24(1):29-43
pubmed: 3276531
Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1572-1586
pubmed: 27550750
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1723-30
pubmed: 18628424
Br J Cancer. 2014 Mar 4;110(5):1367-77
pubmed: 24548865
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1039-45
pubmed: 25969506
Breast Cancer Res Treat. 2008 May;109(1):123-39
pubmed: 17578664
J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
pubmed: 25825511
J Natl Cancer Inst. 2014 Sep 15;106(10):
pubmed: 25224496
Am J Epidemiol. 2011 Sep 15;174(6):661-71
pubmed: 21768404
Sci Rep. 2018 Aug 30;8(1):13109
pubmed: 30166604
Am J Epidemiol. 2009 May 15;169(10):1251-9
pubmed: 19318616
Br J Cancer. 2005 Jan 17;92(1):167-75
pubmed: 15597097
Breast Cancer Res Treat. 2002 Mar;72(2):107-15
pubmed: 12038701
Clin Breast Cancer. 2014 Dec;14(6):417-25
pubmed: 24970715
J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
pubmed: 11959894
Breast Cancer Res. 2006;8(4):R43
pubmed: 16859501
Int J Cancer. 2016 May 15;138(10):2346-56
pubmed: 26684063
Breast Cancer Res Treat. 2012 Jan;131(1):159-67
pubmed: 21830014
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1115-20
pubmed: 24718280
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68
pubmed: 15466970
J Natl Cancer Inst. 2004 Feb 4;96(3):218-28
pubmed: 14759989
Cancer Res. 2018 Oct 15;78(20):6011-6021
pubmed: 30185547
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626
pubmed: 29593010
Breast Cancer Res Treat. 2013 Nov;142(1):165-75
pubmed: 24136668
Cancer Prev Res (Phila). 2011 Sep;4(9):1457-64
pubmed: 21622728
Breast Cancer Res. 2019 Mar 12;21(1):40
pubmed: 30867002
Am J Epidemiol. 2008 Jan 15;167(2):230-9
pubmed: 17965112
Ann Intern Med. 2019 Jan 1;170(1):22-30
pubmed: 30534999
BMC Cancer. 2013 Dec 09;13:584
pubmed: 24321460
Cancer Causes Control. 2013 Apr;24(4):731-9
pubmed: 23380944
Lancet Oncol. 2013 Sep;14(10):1009-19
pubmed: 23890780
J Natl Cancer Inst. 2015 Jun 17;107(9):
pubmed: 26085483
Cancer Causes Control. 2008 May;19(4):391-401
pubmed: 18080775
Breast Cancer Res. 2017 Jan 23;19(1):10
pubmed: 28114999
Breast Cancer Res. 2005;7(3):131-42
pubmed: 15987443
Int J Epidemiol. 2017 Feb 1;46(1):373
pubmed: 28379453
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):270-277
pubmed: 27756774
BMC Cancer. 2013 May 04;13:225
pubmed: 23642215

Auteurs

Esther M John (EM)

Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA.
Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.

Amanda I Phipps (AI)

Department of Epidemiology, University of Washington, Seattle, WA.
Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Lisa M Hines (LM)

Department of Biology, University of Colorado at Colorado Springs, Colorado Springs, CO.

Jocelyn Koo (J)

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.

Sue A Ingles (SA)

Department of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Kathy B Baumgartner (KB)

Department of Epidemiology and Population Health, School of Public Health & Information Sciences, James Graham Brown Cancer Center, University of Louisville, Louisville, KY.

Martha L Slattery (ML)

Department of Medicine, University of Utah, Salt Lake City, UT.

Anna H Wu (AH)

Department of Preventive Medicine, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH